ASCO, Chicago, IL, USA, 1-5 June 2018

PK/PD properties of BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody®, in patients (pts) with advanced/metastatic solid tumors

Christophe Le Tourneau, Josep Tabernero, Rainer Claus, Ralph Fritsch, Francesco Ricci, Elena Elez, Björn Hackanson, Thomas Arnhold, Sascha Keller, Ralph Graeser, Nicolas Isambert 

Le Tourneau et al ASCO 2018 poster



In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.